Ticker
AERI

Price
15.10
Stock movement down
-0.08 (-0.53%)
Company name
Aerie Pharmace
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
734.21M
Ent value
1.20B
Price/Sales
3.65
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
2.58%
3 year return
-12.92%
5 year return
-21.90%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AERI does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.65
Price to Book-
EV to Sales5.97

FINANCIALS

Per share

Loading...
Per share data
Current share count48.62M
EPS (TTM)-1.44
FCF per share (TTM)-0.24

Income statement

Loading...
Income statement data
Revenue (TTM)201.00M
Gross profit (TTM)174.07M
Operating income (TTM)-45.78M
Net income (TTM)-68.74M
EPS (TTM)-1.44
EPS (1y forward)-1.26

Margins

Loading...
Margins data
Gross margin (TTM)86.60%
Operating margin (TTM)-22.78%
Profit margin (TTM)-34.20%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash56.44M
Net receivables63.62M
Total current assets316.97M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets395.55M
Accounts payable7.88M
Short/Current long term debt337.18M
Total current liabilities115.29M
Total liabilities521.26M
Shareholder's equity-125.71M
Net tangible assets-125.71M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-7.19M
Capital expenditures (TTM)4.12M
Free cash flow (TTM)-11.30M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-17.38%
Return on Invested Capital56.69%
Cash Return on Invested Capital9.32%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open15.15
Daily high15.16
Daily low15.09
Daily Volume3.48M
All-time high73.90
1y analyst estimate18.67
Beta0.40
EPS (TTM)-1.44
Dividend per share-
Ex-div date-
Next earnings date2 Nov 2022

Downside potential

Loading...
Downside potential data
AERIS&P500
Current price drop from All-time high-79.57%-12.18%
Highest price drop-93.30%-56.47%
Date of highest drop1 Jun 20229 Mar 2009
Avg drop from high-44.91%-11.38%
Avg time to new high26 days12 days
Max time to new high1034 days1805 days
COMPANY DETAILS
AERI (Aerie Pharmace) company logo
Marketcap
734.21M
Marketcap category
Small-cap
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Employees
376
Investor relations
-
SEC filings
CEO
Vicente J. Anido
Country
USA
City
Durham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best.
September 20, 2022
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
September 20, 2022
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
September 13, 2022
DURHAM, N.C., September 13, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapi...
September 13, 2022
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
September 12, 2022
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
September 12, 2022
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
September 8, 2022
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
September 7, 2022
In this article, we will discuss how hedge funds were right about these 10 small-cap stocks. To skip our detailed analysis of well-performing industries in 2022, go directly and see Hedge Funds Were R...
September 2, 2022
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
September 1, 2022
Next page